EYEnes Yiğit

Enes Yiğit

*This is an algorithmically generated author record based on publicly available information.

Enes Yiğit has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of nonmotor symptoms in myasthenia gravis patients

    by Aysel Tekeşi̇n, Çağla Şi̇şMan, Ufuk Emre Toprak, Alena Sar, Burcu Akalin, Goncagül Koşargeli̇r, Meli̇h Tütüncü, Enes Yi̇ğİt

    Background/aim: Myasthenia gravis (MG) is chronic autoimmune disorder characterized primarily by muscle weakness and fatigue, due to autoantibodies targeting acetylcholine receptor at neuromuscular junction. In this study, we aimed to evaluate non-motor symptoms in myasthenia gravis patients and compare them with disease duration, severity and clinical features.Materials and methods: This prospective study was conducted with thirty-five myasthenia gravis patients and thirty-five healthy volunteers. Total of 35 patients, 17 women and 18 men with mean age of 52.9±13.6 years constituted patient group. Control group consisted of total of 35 participants, 23 women and 12 men with mean age of 46.9±12.2 years. Patient group was applied scales of MG Foundation of America clinical classification, MG Composite and Turkish version of MG Quality of Life 15. For non-motor functions, both in patients and controls; we used the inquiry questionnaires evaluating symptoms of headache, pain, depression, anxiety, sleep, physical activity, cognition, smell and taste. Results: Results revealed prevalent and diverse non-motor symptoms in MG patients. Montreal Cognitive Assessment (MoCA) score and degree of olfactory function in cinnamon in patient group was significantly (p<0.05) lower than control group. Rate of impaired MoCA degree, headache rate, Beck depression score, depression rate, Beck anxiety score, anxiety rate, Pittsburgh Sleep Quality Index (PSQI) score, rate of poor PSQI in patient group was significantly (p<0.05) higher than control group.Conclusion: In conclusion, our study emphasizes importance of recognizing and managing non-motor symptoms in MG patients, advocating for multidisciplinary approach to care that addresses both motor and non-motor manifestations. By expanding our understanding of MG's systemic impact and exploring new treatment modalities, we can improve lives of those living with this complex autoimmune disorder. Further research is needed to elucidate pathogenic mechanisms underlying these non-motor manifestations, which will be pivotal in developing more targeted and effective therapeutic strategies.


  • Open Access

    Evaluation of adropin indices and PCSK9 in non-diabetic men with severe obstructive sleep apnea

    by Levent Deniz, Hale Aral, Özlem Akdoğan, Hilmi Furkan Arslan, Enes Yiğit

    Objectives: We aimed to investigate the relationship among proprotein convertase subtilisin/kexin type 9 (PCSK9), adropin levels, inflammation, and sleep variables in non-diabetic males with severe obstructive sleep apnea (OSA). Methods: This cross-sectional study included adults aged 18 to 65 who underwent polysomnography due to sleep problems between July 2019 and August 2020. Participants were grouped based on their apnea-hypopnea index (AHI). We included 32 males with simple snoring (AHI2 , compared to the controls, blood pressure values, interleukin-6 (IL-6), white blood cell (WBC) count, systemic inflammation response index, neutrophil, monocyte counts were found to be higher, but adropin/BMI, adropin/waist circumference, adropin/neck circumference were significantly lower. Adropin/BMI had the highest correlation coefficient with IL-6. Although there was no significant difference in PCSK9 levels among the groups, PCSK9 was independently correlated with the WBC and its subsets. Conclusions: Our study is of clinical importance as it is the first to show a relationship between PCSK9 and inflammation markers in severe OSA. Also, this study demonstrated the potential value of adropin, in combination with BMI, as a valuable indicator for assessing inflammation and OSA severity.

  • Role of Fungal Species in the Etiology of Nasal Polyposis

    by Ozan Özdemir, Aysel Karataş, Tolga Kırgezen, Mert Ahmet Kuşkucu, Enes Yiğit, Özlem Doğan, Özgür Yiğit

  • Effect of the povidone iodine, hypertonic alkaline solution and saline nasal lavage on nasopharyngeal viral load in COVID‐19

    by Aysegul Batioglu‐Karaaltin, Ozgur Yigit, Dogan Cakan, Ozer Akgul, Enes Yigit, Yetkin Zeki Yilmaz, Kays‐I Burak Cakir, Gamze Ciftci, Nihal Seden Boyoğlu, Abdurrahman Cagliyan, et al.

    Objective: The present study aimed to investigate the in vivo activity of nasal irrigation (NI) with saline, NI with povidone–iodine (PVP–I) 1%, NI with a mix of hypertonic alkaline and PVP–I 1% against Severe acute respiratory syndrome‐coronavirus‐2 (SARS‐CoV‐2).Design: This study was a prospective randomised clinical trial.Setting: A multicenter study involving tertiary care centres.Participants: The study included adult outpatients whose qualitative SARS‐CoV‐2 RT‐PCR tests in nasopharyngeal swabs were positive. One hundred twenty patients were divided into four equal groups. Standard COVID‐19 treatment was given to Group 1, NI containing saline was added to patients' treatment in Group 2, NI containing 1% PVP–I solution was added to patients' treatment in Group 3, and NI containing 1% PVP–I solution and the hypertonic alkaline solution was added to patients' treatment in Group 4.Main Outcome Measures: On the first day of diagnosis (Day 0), nasopharyngeal swab samples were taken, on the third and fifth days the nasopharyngeal viral load (NVL) reduction in quantitative RT‐PCR test was calculated.Results: Between the zeroth to third days and zeroth to fifth days, the NVL reduction was significant in all groups (p < .05). In paired comparisons of groups, the NVL decrease in Group 4 in the first 3 days was significantly lower than all groups (p < .05). The NVL decrease in Groups 3 and 4 in the first 5 days were significantly lower than Group 1 (p < .05).Conclusion: This study revealed that the use of NI of 1% PVP–I and the hypertonic alkaline solution mixture was more effective in reducing NVL.


  • Open Access

    Do the Age of Implantation, the Widths of Internal Acoustic Canal and Bony Cochlear Nerve Canal Affect the Auditory Performance of Primary School Children with Bilateral Cochlear Implants?

    by Ozan Özdemir, Abdullah Soydan Mahmutoğlu, Enes Yiğit, Mustafa Çakır, Özgür Yiğit

    To reveal the correlation between implantation age, the internal acoustic canal (IAC) width, bony cochlear nerve canal (BCNC) width, and auditory performance in primary school children with bilateral cochlear implantation (CI). Preoperative IAC and BCNC widths of 57 pre-lingually deaf children aged 7–11 years who had previously undergone bilateral CI in our institution were reviewed and cut-off values were calculated. Twenty-four patients who had additional problems and could not attend school and those who refused to participate in the study were excluded. The remaining 33 were invited to the hospital, and their speech perception tests, and language development scores were analyzed (16 of 33 patients had been operated on before the age of 24 months). The cut-off values calculated from the 114 ears of 57 patients were 3.86 mm for IAC width and 1.56 mm for BCNC width. The auditory performances of the 33 patients after CI were not significantly different in the narrow and normal width groups. However, speech perception test results, and language development scores of patients implanted before the age of 24 months were significantly higher. There are some studies showing that children with bilateral sensorineural hearing loss have narrower IAC and BCNC widths. However, we concluded that the widths of the IAC and the bone cochlear nerve canal did not affect auditory performance. We found that implantation age is the single most important determinant of speech-language development after CI.


  • Open Access

    Thermal Characteristics of Different Types of Cochlear Implants in Pediatric Cochlear Implant Users: AComparative Digital-Infrared Thermal Imaging Analysis

    by Enes Yigit, Okan Ovunc, Nihal Seden, Ozan Ozdemir, Ozgur Yigit

    BACKGROUND: This study aimed to evaluate thermal characteristics of different types of pediatric cochlear implants METHODS: A total of 39 pediatric patients using Med-El (Synchrony®), Cochlear (Nucleus®), or Advanced Bionics (HiRes 90K®) type of cochlear implants were included. A digital infrared thermal imaging analysis was performed to measure the heating over the implant and the tissue heat- ing of the skin below and around the device, while skin thickness and visual analog scale scores were also recorded. RESULTS: Over the implant, heating values were significantly higher in the on-mode vs. off-mode of device for each type of implant (P ranged from <.05 to <.001). The implants groups were similar in terms of skin thickness, visual analog scale scores, on-mode values for heating over the implant, and the heating of the skin (below or around the device; <36°C for each), while the off-mode values for heating over the implant were significantly higher in the Med-El (Synchrony®) implants compared to other implants (median 31.75 vs. 31.30 and 30.20°C, P = .001). Skin thick- ness was negatively correlated with the heating over the implant (off-mode, r=−0.708, P < .001) and heating of the skin (around the device, r = −0.479, P = .028) in Advanced Bionics (HiRes 90K®) implants. CONCLUSION: Our findings emphasize that there is no hazard or discomfort from a cochlear implant in terms of heating of skin and no significant difference between 3 implant types in terms of skin thickness or tissue heating, whereas indicate the increased likelihood of thermal characteris- tics of implant to differ with respect to skin thickness in Advanced Bionics (HiRes 90K®) users. Cite this article as: Yigit E, Ovunc O, Seden N, Ozdemir O, Yigit O. Thermal characteristics of different types of cochlear implants in pediatric cochlear implant users: A comparative digital-infrared thermal imaging analysis. J Int Adv Otol. 2022;18(4):278-284.


  • The Impact of Isotretinoin Therapy on the Nasal Skin Thickness and Elasticity: An Ultrasonography and Elastography Based Assessment in Relation to Dose and Duration of Therapy

    by Enes Yigit, Ibrahim Taskin Rakici, Nihal Seden, Vildan Manav, Ismail Kaygisiz, Ozgur Yigit

    Background This study aimed to evaluate the impact of isotretinoin therapy on the nasal skin thickness and elasticity with regard to implications for rhinoplasty Methods A total of 40 acne vulgaris patients (mean±SD age: 20.9 ± 3.0 years, 65.0% were females) initiating oral isotretinoin treatment (0.25 mg/kg/day, n = 16 or 0.5 mg/kg/day, n = 24) were included in this prospective 4-month isotretinoin follow-up study. Ultrasonography assessments regarding nasal skin thickness (dermis and soft tissue) and elastography were repeated at second and fourth months of treatment. Results No significant difference was noted between isotretinoin dose groups in terms of second month and fourth month nasal skin thickness (dermis and soft tissue) values measured at any region. Each dose revealed significant decrease in dermis and soft tissue thickness from baseline at any region (p ranged < 0.001 to < 0.001), while only fourth month values at nasal tip and second month values at rhinion for dermis and only fourth month values at rhinion and glabella for subcutaneous tissue significantly differed from baseline (p < 0.01 for each) in the 0.25 mg and 0.50 mg dose groups, respectively. Elastography values at fourth month of isotretinoin treatment were significantly higher than pre-treatment and second month values in both 0.25 mg (90.4 ± 20.6 vs. 59.5 ± 21.8 and 76.4 ± 22.9, p < 0.01 for each) and 0.5 mg (86.7 ± 20.6 vs. 61.8 ± 23.2 and 76.9±24, p < 0.01 for each) dose groups. Conclusions In conclusion, our findings revealed the association of isotretinoin treatment with a significant decrease in dermis and subcutaneous soft tissue thickness measured at each anatomical landmark, regardless of the treatment dose. Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266